A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
Clinical trial NCT02207725 · COMPLETED
Trial details
- NCT number
- NCT02207725
- Sponsor
- Portola Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-01
- Primary completion
- 2015-04-01
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.